Hepatitis E Seroprevalence in Dialysis in Southern Reunion Island

Guiserix, J; Finielz, Paul; Ramdane, Mohamed; Rajaonarivelo, P.

doi:10.1159/000189314

Cited by 1 publication

(1 citation statement)

References 5 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The characteristics of eligible studies in this systematic review and meta-analysis are summarized in Table 2. The largest study [18] included 420 and the smallest [19] [28] 1996 Italy 193 59.5 ELISA Guiserix [29] 1996 France 62 -ELISA Psichogiou [18] 1996 Greece 420 57.3 ELISA Fabrizi [30] 1997 Italy 204 61.1 ELISA Parana [22] 1997 Brazil 392 -ELISA Abdel Hady [31] 1998 Egypt 96 -ELISA Arinsoy [32] 1998 Turkey 52 -ELISA Gessoni [33] 1998 Italy 247 -ELISA Dalekos [34] 1998 Greece 211 -ELISA/Western blot Sylvan [35] 1998 Sweden 182 -ELISA Agarwal [36] 1999 India 64 38 ELISA Kilic [37] 1999 Turkey 70 -ELISA Mateos [38] 1999…”

Section: Study Characteristicsmentioning

confidence: 99%

Seroepidemiology of hepatitis E virus infection in patients undergoing maintenance hemodialysis: Systematic review and meta‐analysis

et al. 2020

View full text Add to dashboard Cite

Background: Hepatitis E virus (HEV) infection is an important emerging health issue in patients on hemodialysis (HD). To date, numerous studies have reported controversial findings regarding the seroprevalence of HEV among this high-risk group around the world. The aim of the present study was to estimate the overall seroprevalence of HEV in HD patients. Methods: A systematic literature search was carried out using PubMed, Web of Science, Scopus, Embase, and Google scholar from inception to January 10, 2020 with standard keywords. Pooled seroprevalence estimates with 95% confidence intervals (CI) were calculated using a random intercept logistic regression model. Results: A total of 56 studies met the inclusion criteria compromising 9483 HD patients. The pooled seroprevalence of HEV was estimated 9.31% (95%CI: 6.83%-12.57%). The seroprevalence of HEV was increased from 6.6% between the years of 1994 and 2000 to 11.13% from the year of 2016 to 2020. Blood transfusion was associated with a nearly twofold increase in the rate of HEV seropositivity (OR=1.99; 95%CI: 1.50-2.63, P value < 0.0001, I 2 =6.5%). Conclusions: Our results indicated an increased exposure of HD patients with HEV infection over the last decade. We concluded that blood transfusion, age and duration of HD are considerable risk factors for acquiring HEV infection among HD patients.

show abstract